OnKure Therapeutics (OKUR) Capital Expenditures (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Capital Expenditures came in at $5000.0 in Q1 2026, down 72.22% YoY from $18000.0 in Q1 2025, and down 44.44% on a QoQ basis from $9000.0 in Q4 2025.
OnKure Therapeutics (OKUR) Capital Expenditures (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Capital Expenditures data on file, last reported at $5000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 72.22% year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33000.0 (down 45.9% YoY) and the FY2025 annual result came in at $46000.0, down 11.54% from the prior year.
- Capital Expenditures eased to $5000.0 in Q1 2026, from $9000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $250000.0 in Q4 2022 to a low of -$166000.0 in Q3 2023.
- A 5-year average of $40882.4 and a median of $15000.0 in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures jumped 300.0% — and 2023, when it tumbled 692.86%.
- Tracing OKUR's Capital Expenditures over 5 years: stood at $250000.0 in 2022, then decreased by 6.0% to $235000.0 in 2023, then slumped by 93.62% to $15000.0 in 2024, then sank by 40.0% to $9000.0 in 2025, then sank by 44.44% to $5000.0 in 2026.
- The last three Capital Expenditures figures came in at $5000.0 (Q1 2026), $9000.0 (Q4 2025), and $6000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,000.00 |
| Jun 30, 2026 | 3,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Sep 30, 2024 | 18,000.00 |
| Sep 30, 2024 | 18,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |